A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
Do‐Youn Oh(Seoul National University Hospital), Young Su Noh(Hanmi Pharmaceutical (South Korea)), Sun Young Rha(Yonsei University), Paul Rhee(Hanmi Pharmaceutical (South Korea)), Michael Chisamore(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hosung Jang(University of Georgia), Jiyeon Yoon(Seoul National University), Jun‐Eul Hwang(Chonnam National University Hwasun Hospital), Sang Cheul Oh(Korea University), Jaeyong Cho(Severance Hospital), Keun‐Wook Lee(Seoul National University Bundang Hospital), Dae Young Zang(Second Affiliated Hospital of Dalian Medical University), Taewan Kim(VA North Texas Health Care System), William Ho(Baker Heart and Diabetes Institute), Eunhye Baek(Hanmi Pharmaceutical (South Korea)), Min-Hee Ryu(Ulsan College), Byoung Yong Shim(The Catholic University of Korea St. Vincent's Hospital), Sooa Jung(Hanmi Pharmaceutical (South Korea)), Jeeyun Lee(Samsung Medical Center)
Cited by 0
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Multi-criteria decision making approaches for supplier evaluation and selection: A literature review
|European Journal of Operational Research|2009|2.2k
Supply chain risk management: a literature review
|International Journal of Production Research|2015|1.3k
Integrated analytic hierarchy process and its applications – A literature review
|European Journal of Operational Research|2007|1.2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k